Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4039709 | 0.92 | PDE5A (0.74) | PDE5AKCNH2 | |
| SCHEMBL4472474 | 0.90 | PDE5A (0.60) | PDE5AKCNH2CCNA2CDK2CCNA1 | |
| SCHEMBL5246604 | 0.90 | PDE5A (0.64) | PDE5AKCNH2 | |
| SCHEMBL4043243 | 0.88 | PDE5A (0.67) | PDE5AKCNH2CCNA2CDK2CCNA1 | |
| SCHEMBL5245486 | 0.88 | PDE5A (0.61) | PDE5AKCNH2 | |
| SCHEMBL4043003 | 0.88 | PDE5A (0.53) | PDE5AKCNH2 | |
| SCHEMBL14357667 | 0.87 | PDE5A (0.52) | PDE5AKCNH2CCNA2CDK2CCNA1 | |
| SCHEMBL8276272 | 0.86 | PDE5A (0.69) | PDE5AKCNH2 | |
| SCHEMBL4046589 | 0.84 | PDE5A (0.63) | PDE5AKCNH2 | |
| SCHEMBL4039232 | 0.82 | PDE5A (0.63) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569572-B2 | Pyrazolo[4,3-D]pyrimidines | PFIZER INC (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1742950-B1 | PYRAZOLO[4,3-D] PYRIMIDINES | PFIZER LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | BELL ANDREW SIMON | 2008-11-27 | — | — | US | disclosed |
| EP-1809632-A2 | PYRAZOLO[4,3-D]PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-07-25 | — | — | EP | disclosed |
| EP-1742950-A1 | PYRAZOLO[4,3-D] PYRIMIDINES | Pfizer Limited (GB) | 2007-01-17 | — | — | EP | disclosed |
| WO-2006046135-A2 | PYRAZOLO[4,3-D] PYRIMIDINE DERIVATIVES USEFUL AS PDE-5 INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005097799-A1 | PYRAZOLO`4,3-D! PYRIMIDINES | PFIZER LIMITED (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | DPYD, TYMS, TYMP | PDE5A 1707/4885KCNH2 794/4885CCNA2 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.